About this trial
Friedreich's ataxia (FRDA) is an autosomal recessive disease characterized by loss of coordination and cardiomyopathy. It is the most common form of inherited ataxia with an incidence in 1/50,000 in the Caucasian population. FRDA is associated with progressive damage to the nervous system, resulting in symptoms ranging from gait disturbance to speech problems, as well as diabetes and heart disease. The heart disease manifests as cardiomyopathy, and is responsible for approximately 60% of deaths from FRDA. This study is designed to characterize the cardiac manifestations of the disease using exercise, MRI, ECHO and serum parameters, in the context of the neurological disease. In addition, this study will demonstrate that corneal confocal microscopy (CCM) may also provide a biomarker for FRDA.
Eligibility criteria
Qualifiers
Males and females, age 12 to 50
Willing and able to provide informed consent (adolescents will need to provide assent and a parent to provide consent)
Definitive diagnosis of FRDA, based on clinical phenotype and genotype
Left ventricle ejection fraction measured by ECHO of >35% (If results of an ECHO are not available for a potential subject, then an ECHO will first be performed and subjects with an LVEF <35% will not be required to perform the CPET)
Disqualifiers
Signs and symptoms of cardiac failure
Moderate to severe atrial or ventricular arrythmias
History of angina pectoris
Implanted pacemaker and/ or defibrillator or any other device that would preclude MRI assessment
Trial design
Treatments tested in this trial
- Cardiac magnetic resonance imaging (CMR)
- Exercise-stress test
- Echocardiogram (ECHO)
- Cardiac-related blood studies